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M ultiple myeloma (MM) is caused by tumori-genically transformed plasma cells,  a termi-
nally differentiated form of B lymphocytes,  and is char-
acterized by the production of an abnormal protein 
called monoclonal immunoglobin (M-protein) by 
tumor cells.  Even in the novel agent era this disease is 
intractable,  and it exhibits serious clinical symptoms,  
including hypercalcemia,  renal insufficiency,  anemia,  
and bone osteolytic changes (the so-called CRAB crite-
ria) [1].
Nonetheless,  drastic improvements in therapeutic 
outcomes have been achieved by treatment with high-
dose melphalan plus autologous stem cell transplanta-
tion (ASCT),  as well as by novel agents such as borte-
zomib,  lenalidomide,  and thalidomide.  However,  
these treatments have failed to improve long-term sur-
vival in elderly patients,  who are generally ineligible for 
ASCT.  Thus,  the greatest benefits of these treatments 
are limited to patients younger than 70 years,  mainly 
owing to adverse events (AEs) [2].  Moreover,  the 
European Myeloma Network recommends reducing the 
dosage of various agents based on a patient’s age and 
other risk factors [3].
The two following options are recommended for 
elderly patients based on data from randomized phase 
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Elderly multiple myeloma (MM) patients,  who are generally ineligible for transplantation,  have high risks of 
death and treatment discontinuation,  and require a regimen incorporating novel agents that balance safety,  
tolerability,  and efficacy.  We evaluated alternating bortezomib-dexamethasone and lenalidomide-dexametha-
sone treatments administered over a 63-day cycle in transplant-ineligible elderly patients with newly diagnosed 
MM.  Subcutaneous bortezomib 1.3 mg/m2 was administered weekly on Days 1,  8,  15,  and 22; oral lenalido-
mide 15 mg daily on Days 36-56; and oral dexamethasone 20 mg on Days 1,  8,  15,  22,  36,  43,  50,  and 57 for 
6 cycles.  The primary endpoint was the overall response rate.
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III trials: bortezomib [intravenous (iv)]/melphalan/
prednisone (BMP),  based on the VISTA trial [4],  and 
lenalidomide plus low-dose dexamethasone (Ld),  based 
on the FIRST trial [5].  In Japan,  both BMP and Ld have 
been approved in frontline settings.
The VISTA trial reported that,  compared with con-
ventional melphalan-prednisone therapy,  treatment 
with BMP significantly extended progression-free sur-
vival (PFS) and overall survival (OS).  However,  BMP 
therapy was associated with a high incidence of AEs of 
grade 3 and higher,  and only 59% of the treatment 
groups completed all nine cycles of the regimen [4].  
Combination therapy with bortezomib-dexamethasone 
(BD) has also been examined,  notably by the UPFRONT 
trial,  a US community-based phase IIIB study designed 
to compare three front-line bortezomib(iv)-based regi-
mens in ASCT-ineligible patients with MM.  Outcomes 
in elderly MM patients (median age 73 years) were 
compared among BD,  BMP,  and BD plus thalidomide 
(BTD) [6] groups.  Analysis conducted at a median of 
42.7 months showed no significant differences in PFS 
among all treatments.  BMP was associated with the 
highest rate of hematologic toxicity,  whereas peripheral 
neuropathy (PN) of grade ≥ 2 was reported in 47% of the 
BTD arm of the study.  The rates of AEs and discontin-
uations due to AEs appeared higher with BTD than 
with BD or BMP.  These findings suggested that a BD 
regimen in which bortezomib is administered twice 
weekly is a treatment option with balanced efficacy and 
safety for elderly MM patients [6].  Likewise,  modifying 
the frequency of bortezomib administration in BMP 
therapy to once per week has been shown to reduce tox-
icity and discontinuation while maintaining efficacy,  as 
shown by other trials conducted in Italy (GIMEMA) [7] 
and Spain (PETHEMA) [8].  Meta-analysis of the data 
of 1435 individual patients enrolled in 4 European phase 
III trials (GISMM-2001,  HOVON 49,  GEM05MAS,  
and GIMEMA MM0305) involving thalidomide and/or 
bortezomib(iv) indicated that an age of ≥ 75 years and 
treatment discontinuation due to AEs have significant 
negative impacts on the survival of elderly patients [9].  
To improve outcomes in elderly patients aged ≥ 75 years,  
the development of a treatment that can further reduce 
toxicity and discontinuation is necessary.
Based on the results of an open-label,  randomized 
MMY-3021 phase III study comparing subcutaneous 
(sc) and iv administration of bortezomib,  sc bortezo-
mib administration is safe and effective [10].  Currently,  
once-a-week sc administration of bortezomib is widely 
used in clinical practice.
The FIRST trial compared the combination of mel-
phalan-prednisone-thalidomide (MPT) versus Ld for 
18 cycles and MPT versus Ld until progression (PD) in 
1623 patients with ASCT-ineligible,  newly diagnosed 
multiple myeloma (NDMM) [5].  PFS was higher in the 
PD arm than in the other 2 arms,  and OS was higher in 
the PD arm than in the MPT arm.  Based on the results 
of the trial,  the lenalidomide plus high-dose dexameth-
asone (LD) regimen is considered the new standard of 
care for patients with NDMM who are unable to tolerate 
triplet therapy owing to advanced age,  poor perfor-
mance status,  or comorbidities.  In contrast,  the dis-
continuation rate in the PD arm was 87%,  with 51% 
discontinuation due to disease progression and 12% due 
to AEs,  thereby showing the difficulty of achieving a 
sustained therapeutic effect with a single novel agent.
To further optimize treatment outcomes in this 
patient population,  a triplet combination of bortezo-
mib plus LD (LBD) administered using a modified dose 
and schedule (LBD-lite) was evaluated [11].  The LBD-
lite regimen consisted of a 35-day cycle of lenalidomide 
(15 mg,  Days 1-21) plus once a week sc administration 
of bortezomib and dexamethasone.  A total of 53 
NDMM patients were enrolled,  with a median age at 
diagnosis of 73 years.  The majority of patients experi-
enced treatment-related AEs,  including fatigue (74%) 
and PN (62%),  but these AEs were mostly of grade 1/2 
severity.  The investigator-reported overall response rate 
(ORR) was 86%,  including 66% ≥ very good partial 
response (VGPR).  After a median follow-up of 30 
months,  the median PFS was 35.1 months,  whereas the 
median OS had not been reached.  Among the 36% of 
patients who discontinued therapy prior to completion,  
12% had progressive disease,  4% showed treatment 
toxicity,  and 2% switched to non-protocol therapy.  On 
the basis of these results,  modified LBD was considered 
to be a tolerated and effective option for elderly ASCT-
ineligible NDMM patients.
Currently,  although the benefits of these novel 
agents have become clear,  the majority of patients die 
after a series of relapses.  An analysis of molecular 
abnormalities associated with onset and progression 
using next-generation sequencing revealed that sub-
clonal diversity was found even at diagnosis and showed 
progression using the Darwinian branching model [12].  
Therapeutic approaches that depend on a single-class 
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treatment result in the proliferation and domination of 
a minor clone in the tumor population.  Therefore,  at 
the induction therapy,  entire clones of myeloma cells 
must be suppressed by combining agents with different 
mechanisms.  Furthermore,  their continuous adminis-
tration may also be essential.
There is little evidence supporting the strategy of 
using alternating chemotherapy regimens to treat MM.  
Sequential and alternating regimens with BMP and Ld 
have recently been compared in GEM2010MAS65,  an 
international phase II trial,  which hypothesized that the 
alternating strategy would minimize the emergence of 
resistant clones and would reduce the cumulative toxic-
ity [13].  A total of 242 patients were randomized to 
receive a sequential regimen consisting of 9 cycles of 
BMP followed by 9 cycles of Ld or the same regimens in 
an alternating approach.  After a median follow-up of 27 
months,  the median PFS was 30 months in both the 
sequential and alternating arms (p = not significant),  
whereas the median OS had not been reached.  No sig-
nificant differences in the frequency of the toxicity pro-
file were observed between the 2 arms,  but all early 
deaths and 71% of early discontinuations occurred in 
patients aged ≥ 75 years.  Considering the results of this 
trial,  alternating treatment for patients aged ≥ 75 years 
needs to be optimized,  such as through dose modifica-
tion of the agents,  the use of a fixed period,  and the 
exclusion of alkylators or the use of alkylator-free regi-
mens.
In our trial,  we evaluated alternating Bd and Ld 
(alkylator-free regimen) and investigated the regimen 
with balanced safety,  tolerability,  and efficacy in elderly 
patients with ASCT-ineligible NDMM.  Moreover,  we 
analyzed chromosomal abnormalities in the patients by 
fluorescence in situ hybridization (FISH),  and examined 
whether the alternating strategy suppresses clonal evo-
lution.
Trial design. In this phase II,  open-label,  sin-
gle-arm,  multicenter trial,  we evaluate the efficacy and 
safety of alternating Bd and Ld as an induction therapy 
for NDMM patients older than 75 years (who are ineli-
gible for ASCT).  This trial was approved by the Central 
Ethics Review Committee for Clinical Research of the 
National Hospital Organization on 20 July 2014 (H26-
0320002).  This study has been registered in the Clinical 
Trial Registry (UMIN-CTR) (UMIN000013773).
Endpoints
Primary endpoints. ORR during the period of 
administration of chemotherapy alternating between Bd 
and Ld: proportion of eligible patients whose best 
responses were a stringent complete response,  complete 
response (CR),  VGPR,  and partial response (PR).  The 
response is evaluated according to the International 
Myeloma Working Group Uniform Response Criteria [14].
Secondary endpoints
•AEs
•Proportion of treatment continuation: the pro-
portion of patients who have continued the study 
treatment for up to 6 cycles without discontinua-
tion due to AE or progression of disease among 
enrolled patients.
•CR rate: proportion of eligible patients whose best 
response was a CR.
•VGPR: proportion of eligible patients whose best 
response was a VGPR.
•PFS: duration from the start of treatment to the 
first event of progression,  relapse,  or death due to 
any cause.  Patients who survive without progres-
sion are censored at the last day for which no 
progression was confirmed.
•OS: duration from the start of treatment to death 
due to any cause.  Patients who survive are cen-
sored at the last day of confirmed survival.
•Time to response (TTR): duration from the start 
of treatment to the first response above PR.  
Patients without a response above PR are censored 
at the following events: 1) the longest follow-up 
period in patients with progression,  and 2) the 
last evaluation date in patients without progres-
sive disease and relapse.
Eligibility Criteria
Inclusion criteria
 1. Patients aged older than 75 years.
 2.  Patients with symptomatic MM newly diag-
nosed by the WHO criteria,  and who are inel-
igible for ASCT.
 3.  Patients with measurable disease: an M-protein 
level ≥ 0.5 g/dL for IgG,  IgA,  or IgM type 
myeloma; an M-protein level ≥ 0.05 g/dL for 
IgD type myeloma; or urinary M-protein 
excretion ≥ 200 mg/24-h.
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 4.  Patients with an Eastern Cooperative Oncology 
Group (ECOG) performance status of ≤ 2,  or 3 
owing to osteolytic lesions alone.
 5.  Patients who meet the following criteria of the 
pretreatment clinical laboratory parameters:
•Transaminases (AST,  ALT) < 3.0 × the upper 
limit of normal
・ Creatinine clearance ≥ 30 mL/min
•Absolute neutrophil count ≥ 1.0 × 109/L
•Platelet count ≥ 50 × 109/L
•Ejection fraction ≥ 50%
•PaO2 ≥ 60 mmHg or SpO2 ≥ 93%
 6.  Patients who agree to register for the Revision 
of Procedures for Appropriate Management of 
Revlimid® and Pomalyst® (RevMate®),  and 
comply with the contents.
 7.  Patients who were notified of and provided with 
a sufficient explanation of the contents of this 
study,  and who then provide consent in writing 
to participate in the study by their free will.
Exclusion criteria
 1.  Patients with plasma cell leukemia,  cardiac 
amyloidosis,  or POEMS syndrome.
 2.  Patients who have PN of grade ≥ 2.
 3.  Patients who have uncontrolled liver dysfunc-
tion,  renal dysfunction,  heart failure,  impaired 
respiratory function,  diabetes,  or hypertension.
 4.  Patients with concurrent tuberculosis,  herpes 
simplex keratitis,  systemic fungal disease,  or 
active infection.
 5.  Patients who have had a recent operation.
 6.  Patients who have had a myocardial infarction 
within 6 months of enrollment or deep vein 
thrombosis/pulmonary embolism within 
3 years.
 7.  Patients who have active and advanced double 
cancer (simultaneous or within 5 years post- 
remission).
 8.  Patients who are positive for hepatitis B antigen,  
hepatitis C antibody,  or HIV antibody.
 9.  Patients with pneumonitis (interstitial pneumo-
nia) or pulmonary fibrosis in clinical practice,  
or with abnormal (high-resolution) chest CT 
findings in the bilateral lungs regardless of the 
presence or absence of symptoms.
10.  Patients with hypersensitivity to boron or man-
nitol.
11.  Patients with psychiatric diseases or psycholog-
ical symptoms.
12.  Patients otherwise judged inappropriate to par-
ticipate in this study.
Treatment Methods
Interventions. Patients will be enrolled in the 
trial within 4 weeks of diagnosis and begin treatment 
according to the protocol shown in Fig. 1.  A physician 
will decide whether each patient will receive treatment 
in an inpatient or outpatient setting.
Patients will receive Bd therapy from Days 1-35 (for 
35 days),  and Ld therapy from Days 36-63 (for 28 days).  
Patients will undergo a total of six treatment cycles,  
with each cycle consisting of a 63-day regimen,  as men-
tioned above.  The starting doses of bortezomib and 
lenalidomide will be adjusted on the basis of the 
patients’ age,  general condition,  and renal function.
The scheme of this study is shown in Fig. 2
Bd therapy. Patients will be administered sc bor-
tezomib 1.3 mg/m2 and oral dexamethasone 20 mg on 
Days 1,  8,  15,  and 22.  The site of bortezomib admin-
istration will be rotated between sessions to avoid con-
secutive injections at the same site (e.g.,  the left thigh,  
right thigh or abdomen).  Operators will pull the 
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Patient enrollment
63 days
(9 weeks)
・
・
・
63 days (9 weeks) × 6
cycles = 54 weeks 
Follow-up
Bd therapy (35 days)
Bortezomib 1.3 mg/ｍ2 SC - Days 1, 8, 15, 22
Dexamethasone 20 mg PO - Days 1, 8, 15, 22
Ld therapy (28 days)
Lenalidomide 15 mg PO - Days 36-56
Dexamethasone 20 mg PO - Days 36, 43, 50, 57 
Bd therapy (35 days)
Bortezomib 1.3 mg/m2 SC - Days 1, 8, 15, 22
Dexamethasone 20 mg PO - Days 1, 8, 15, 22
Ld therapy (28 days)
Lenalidomide 15 mg PO - Days 36-56
Dexamethasone 20 mg PO - Days 36, 43, 50, 57
???? ?　 ?Study design.  
PO,  by mouth (per os); SC,  subcutaneous injection.
syringe plunger back slightly after insertion to verify the 
absence of regurgitation,  ensuring that nerve damage is 
avoided.
Bortezomib administration will be suspended upon 
observation of non-hematologic (grade 3 +; except for 
PN and neuropathic pain) or hematologic AE (grade 4),  
as defined by the Common Terminology Criteria for 
Adverse Events (ver. 4.0).  Patients who recover will 
resume administration at a reduced dose.  Bortezomib 
administration will be discontinued and patients will be 
withdrawn from the trial if these AEs fail to subside,  or 
if an AE recurs even with the minimum dose.  In addi-
tion,  the dosage will be lowered in the event of PN or 
neuropathic pain.  If a patient experiences fluctuation in 
body weight of ± 5 kg or greater after the start of treat-
ment,  their body surface area will be remeasured to 
recalculate the appropriate dose.
Dexamethasone may be suspended or administered 
at a reduced dose at the physician’s discretion if an AE 
occurs.
Ld therapy. Following Bd therapy,  patients will 
be administered lenalidomide 15 mg on each of Days 
36-56 and dexamethasone 10 mg on Days 36,  43,  50,  
and 57.
The lenalidomide dosage will be reduced in patients 
with poor renal function (including at the initial dose).  
Moreover,  the lenalidomide dosage will also be reduced 
(or suspended) if an AE occurs.
If an AE occurs in Bd therapy,  dexamethasone may 
be suspended or administered at a reduced dose at a 
physician’s discretion.
Statistical Considerations
Sample size. One trial reported that Ld therapy 
achieved an ORR of 70.4% in untreated MM patients 
aged 75 years or older [15].  On the other hand,  the 
EVOLUTION study observed ORRs of 85% and 88% for 
bortezomib-lenalidomide-dexamethasone and bortezo-
mib-dexamethasone-cyclophosphamide-lenalidomide 
therapies in a population of untreated MM patients [16].  
We expect our alternating bortezomib and lenalido-
mide approach to achieve an ORR of 88%.  Our neces-
sary sample size was calculated to be n = 32,  assuming 
an expected response rate of 88%,  a threshold response 
rate of 70.4%,  α = 0.05 (one-sided),  and β = 0.2 (80% 
power),  based on a binomial distribution.  We set the 
sample size at 35 assuming a dropout rate of 10%.
Statistical methods. ORR,  CR rate,  and VGPR 
will be estimated with 90% confidence intervals (CI).  
Survival curves of PFS,  OS,  and TTR will be calculated 
using the Kaplan-Meier method; CI will be calculated 
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Screening 
Bd/Ld alternate treatment 
Enrolled cases N=35 
Treatment completion 
Follow-up after treatment completion 
(every 2 months) 
Follow-up investigation (PD) 
Evaluation completion 
Follow-up investigation (survivor) 
Observation 
(follow-up) 
period 
Enrollment 
period 
Treatment completion (other than for PD) 
Follow-up after  
administration 
completion 
(every 2 months) 
Treatment completion (for PD) Follow-up after 
administration 
completion 
(every 2 months) 
???? ?　 Study schema
using Greenwood’s formula.  Occurrences of worst-grade 
AEs,  grade-3 + AEs,  and serious AEs will be calculated.
Discussion
Trial participants,  while being monitored for signs 
of relapse,  will be administered alternating chemother-
apy with two agents with different mechanisms cur-
rently considered effective in treating MM: the protea-
some inhibitor bortezomib and the immunomodulator 
lenalidomide.  Our objective is to investigate whether 
these drugs can achieve acceptable safety and efficacy in 
elderly MM patients.  Chromosomal analysis will also be 
conducted to determine whether this alternating strat-
egy proves useful in preventing clonal evolution.
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